Drugs / ATSN-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05878860 | Aug 2023 → Apr 2028 expected | X-linked retinoschisis | Atsena Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATSN-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05878860 ↗ |
| Route | Other | “one-time subretinal injection of ATSN-201 in one eye or both eyes” NCT05878860 ↗ |